Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers

Purpose of reviewInflammatory arthritis diseases including rheumatoid arthritis (RA) are characterized by systemic bone loss and increased risk of osteoporosis and local joint bone erosion. Clinical and biologic parameters of disease activity and inflammation and radiologic findings are poorly sensitive for assessing skeletal changes. More specific biologic markers reflecting systemic quantitative and dynamic changes of bone turnover represent promising adjunctive tools. Recent findingsMore specific and well-characterized biochemical assays especially for type I collagen–based bone resorption markers have been recently developed. Prospective studies indicate that increased levels of some biochemical markers of bone resorption are associated with a more rapid progression of joint destruction in patients with early RA, independently of disease activity and inflammation parameters. This increased bone resorption associated with local bone erosion is likely to be mediated by changes in the balance of the OPG/RANK-L system (receptor activator of nuclear factor κB-ligand and osteoprotegerin) as suggested by the significant association of this ratio in serum and long-term radiologic progression. Besides their well-documented response to bisphosphonate treatment used as adjuvant therapy in patients with glucocorticoid-induced osteoporosis, bone markers may be useful to assess potential beneficial effects of new disease-modifying antirheumatic drugs on systemic bone loss and on progression of joint damage. SummaryRecent evidence suggests that biochemical markers of bone resorption may be useful to predict progression of joint damage in RA. Together with new biochemical markers of cartilage turnover, they are likely to play a major role in assessing effects of treatment on joint damage. Their value in assessing systemic and local bone abnormalities should be explored in other inflammatory arthritis diseases such as ankylosing spondylarthritis.

[1]  J. Iwamoto,et al.  Urinary Cross-linked N-telopeptides of Type I Collagen Levels in Patients with Rheumatoid Arthritis , 2003, Calcified Tissue International.

[2]  M. Karsdal,et al.  The Type I Collagen Fragments ICTP and CTX Reveal Distinct Enzymatic Pathways of Bone Collagen Degradation , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  W. Fraser,et al.  Biochemical markers of bone turnover in seronegative spondylarthropathy: relationship to disease activity. , 1997, British journal of rheumatology.

[4]  P. Delmas,et al.  Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. , 2000, Arthritis and rheumatism.

[5]  C. Li,et al.  Biochemical properties of tartrate-resistant acid phosphatase in serum of adults and children. , 1978, Clinical chemistry.

[6]  D. Keisler,et al.  Bone mineral density and biochemical markers of bone metabolism in ankylosing spondylitis. , 1998, The Journal of rheumatology.

[7]  C. Cooper,et al.  Fracture risk in patients with ankylosing spondylitis: a population based study. , 1994, The Journal of rheumatology.

[8]  J. Risteli,et al.  Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. , 2003, The Journal of rheumatology.

[9]  A. Sabokbar,et al.  Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis. , 2002, Rheumatology.

[10]  K. Federlin,et al.  Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis. , 1995, Annals of the rheumatic diseases.

[11]  M. Nagashima,et al.  Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. , 2003, The Journal of rheumatology.

[12]  H. Franck,et al.  Serum osteocalcin and vitamin D metabolites in patients with ankylosing spondylitis. , 1993, Annals of the rheumatic diseases.

[13]  C. Cooper,et al.  Children and the Risk of Fractures Caused by Oral Corticosteroids , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  S. P. Walton,et al.  Clinical significance of immunoassays for type-5 tartrate-resistant acid phosphatase. , 1999, Clinical chemistry.

[15]  S. Ricard-Blum,et al.  Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. , 1999, Rheumatology.

[16]  P. Geusens,et al.  Biochemical markers of joint tissue turnover in early rheumatoid arthritis. , 2003, Clinical and experimental rheumatology.

[17]  H. Genant,et al.  Bone loss: Quantitative imaging techniques for assessing bone mass in rheumatoid arthritis , 2000, Arthritis Research & Therapy.

[18]  H. Yaziji,et al.  Immunohistochemical detection of tartrate-resistant acid phosphatase in non-hematopoietic human tissues. , 1995, American journal of clinical pathology.

[19]  G. Stein,et al.  Hydroxypyridinium collagen crosslinks in serum, urine, synovial fluid and synovial tissue in patients with rheumatoid arthritis compared with osteoarthritis. , 2003, Rheumatology.

[20]  A. Calin,et al.  Bone mineral density, calcaneal ultrasound, and bone turnover markers in women with ankylosing spondylitis. , 2002, The Journal of rheumatology.

[21]  J. Braun,et al.  Radiologic diagnosis and pathology of the spondyloarthropathies. , 1998, Rheumatic diseases clinics of North America.

[22]  P. Delmas,et al.  Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products. , 1999, Bone.

[23]  O. Henriksen,et al.  Quantitative assessment of synovial inflammation by dynamic gadolinium-enhanced magnetic resonance imaging. A study of the effect of intra-articular methylprednisolone on the rate of early synovial enhancement. , 1996, British journal of rheumatology.

[24]  P. Sambrook,et al.  Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. , 1998, The Journal of rheumatology.

[25]  D. Mellström,et al.  Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis , 2003, Annals of the rheumatic diseases.

[26]  L. Yam,et al.  Tartrate‐Resistant Acid Phosphatase (TRACP): A Personal Perspective , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  P. Emery,et al.  Enthesitis in spondyloarthropathy. , 1999, Current opinion in rheumatology.

[28]  J. Risteli,et al.  Assay for Cross-Linked Carboxyterminal Telopeptide of Type I Collagen (ICTP) Unlike CrossLaps Assay Reflects Increased Pathological Degradation of Type I Collagen in Rheumatoid Arthritis , 2003, Clinical chemistry and laboratory medicine.

[29]  S. Ljunghall,et al.  Serum osteocalcin in rheumatoid arthritis and other inflammatory arthritides: relation between inflammatory activity and the effect of glucocorticoids and remission inducing drugs. , 1986, Annals of the rheumatic diseases.

[30]  W. Maksymowych.  Bisphosphonates for arthritis--a confusing rationale. , 2003, The Journal of rheumatology.

[31]  S. Orloff,et al.  [Bone metabolism in rheumatoid arthritis]. , 1987, Revue medicale de Bruxelles.

[32]  J. Risteli,et al.  Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. , 2000, Bone.

[33]  M. Dougados,et al.  Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. , 1999, The Journal of rheumatology.

[34]  D. Moss.  Changes in enzyme expression related to differentiation and regulatory factors: the acid phosphatase of osteoclasts and other macrophages. , 1992, Clinica chimica acta; international journal of clinical chemistry.

[35]  S. van der Linden,et al.  Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. , 2002, Arthritis and rheumatism.

[36]  V. Szejnfeld,et al.  Systemic osteopenia and mineralization defect in patients with ankylosing spondylitis. , 1997, The Journal of rheumatology.

[37]  A. Collins,et al.  Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures. , 1999, The Journal of rheumatology.

[38]  F. Kainberger,et al.  Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. , 2002, The Journal of rheumatology.

[39]  G. Hein,et al.  Evaluation of free and peptide bound collagen crosslink excretion in different skeletal diseases , 2003, Annals of the rheumatic diseases.

[40]  P. Emery,et al.  Classification of inflammatory arthritis by enthesitis , 1998, The Lancet.

[41]  P. Delmas,et al.  Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[42]  C. Cooper,et al.  The value of bone turnover markers in the prediction of vertebral fracture in patients using oral glucocorticoids. , 2003 .

[43]  B. Dijkmans,et al.  Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. , 2003, Arthritis and rheumatism.

[44]  P. Delmas,et al.  Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation. , 2001, Rheumatology.

[45]  T. Hentunen,et al.  Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[46]  N. Kamatani,et al.  Alkaline Phosphatase in Rheumatoid Arthritis Patients: Possible Contribution of Bone-Type ALP to the Raised Activities of ALP in Rheumatoid Arthritis Patients , 2002, Clinical Rheumatology.

[47]  D. Hume,et al.  Structure, function, and regulation of tartrate-resistant acid phosphatase. , 2000, Bone.

[48]  H. Suominen,et al.  Serum Tartrate-Resistant Acid Phosphatase 5b, but not 5a, Correlates with Other Markers of Bone Turnover and Bone Mineral Density , 2002, Calcified Tissue International.

[49]  M. Cutolo,et al.  Serum Osteocalcin Levels in Premenopausal Rheumatoid Arthritis Patients , 2002, Annals of the New York Academy of Sciences.